Skip to main content

Free Content Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library


Fifty-two adult patients with cerebral malaria were randomly categorized into two groups to receive either quinine dihydrochloride (Qn) alone or a combination of Qn and pentoxifylline (Px). Thirty-two of them received intravenous (i.v.) Qn (group I), and 20 patients (group II) received i.v. Qn along with parenteral Px support (10 mg/kg/day) for the initial 3 days. There was significant improvement in coma resolution time in group II (21.6 ± 13.9 h) in comparison with group I (63.5 ± 19.7 h) (P < 0.001), and mortality was 25% of patients in group I against 10% patients receiving Px adjunct (P > 0.05). Three days post-therapy, serum tumour necrosis factor-α (TNF-α) levels decreased significantly in patients on Px support (day 0 TNF = 415.62 ± 477.80 pg/ml; day 3 TNF = 47.92 ± 27.9 pg/ml; P = 0.0029). There was no significant change in TNF levels in those on quinine alone (day 0 TNF = 477.08 ± 933.90 pg/ml; day 3 TNF = 589 ± 602.3 pg/ml; P > 0.05). There were no serious side-effects necessitating withdrawal of patients receiving Px therapy.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Plasmodium falciparum; human cerebral malaria; pentoxifylline; quinine dihydrochloride; tumour necrosis factor-α

Document Type: Research Article

Affiliations: 1: Department of Internal Medicine, S.C.B. Medical College, Cuttack, India 2: Department of Biochemistry, S.C.B. Medical College, Cuttack, India 3: Division of Immunology, Regional Medical Research Center, Bhubaneswar, India

Publication date: 2003-08-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more